Bhandari Peter, Berezovskiy Reanay, Makhani Salima, Gausman Valerie, Rastogi Neelesh, Braude Sabina
Division of Gastroenterology, Morristown Medical Center, Atlantic Health System, Morristown, NJ.
New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY.
ACG Case Rep J. 2025 Jun 11;12(6):e01731. doi: 10.14309/crj.0000000000001731. eCollection 2025 Jun.
Fulminant infection (CDI) is a rare, severe type of CDI, often associated with extended hospitalizations, significant healthcare costs, and elevated mortality rates. Fecal microbiota transplantation remains an effective treatment modality for patients with fulminant CDI, with high cure rates reported after multiple treatments. Stool frequency, pseudomembrane resolution, and inflammatory markers are routinely monitored to evaluate disease severity and treatment responsiveness. Our case highlights a discordance in these indicators and demonstrates C-reactive protein as an important marker in assessing residual colitis and disease resolution. Comprehensive scoring systems should consider incorporating C-reactive protein and other biomarkers to optimize CDI management.
暴发性艰难梭菌感染(CDI)是一种罕见的严重类型的CDI,通常与住院时间延长、高额医疗费用和死亡率升高相关。粪便微生物群移植仍然是暴发性CDI患者的一种有效治疗方式,多次治疗后报告的治愈率很高。常规监测大便频率、假膜消退情况和炎症标志物,以评估疾病严重程度和治疗反应性。我们的病例突出了这些指标之间的不一致,并证明C反应蛋白是评估残余结肠炎和疾病消退的重要标志物。综合评分系统应考虑纳入C反应蛋白和其他生物标志物,以优化CDI的管理。